US · Healthcare · Medical Devices
EPS came in at 0.07 against a street estimate of -0.16 — a beat of 143.8%.
Analysts rate Delcath Systems Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $24.00.
| Fund | Stake |
|---|---|
| Rosalind Advisors, Inc. | 9.51% |
| BlackRock Inc | 7.80% |
| Vanguard Capital Management, LLC | 3.52% |
| Propel Bio Management LLC | 2.51% |
| Geode Capital Management, LLC | 2.11% |
| State Street Corp | 1.96% |
| Algert Global LLC | 1.67% |
| Millennium Management LLC | 1.63% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Delcath Systems Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.